Saturday, March 21, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Justice Department appeals to reinstate transportation mask mandate

The Centers for Disease Control and Prevention ruled the mandate “necessary,” but an appeal risks creating a precedent that could permanently constrain the agency.

The Biden administration on Wednesday appealed a federal court ruling striking down the mask requirement for passengers on planes, trains, buses and other public transportation after the Centers for Disease Control and Prevention concluded that the mandate was “necessary” to protect the public from the spread of the coronavirus.

The decision came two days after a federal judge in Florida struck down the mask mandate, and set off a rush among airlines, some public transit systems and even Uber and Lyft to abandon mask requirements. Some pilots announced the abrupt change midflight, prompting celebration — but also anxiety — among virus-weary passengers.

While the C.D.C. wants to keep the mandate intact, it is also pressing the appeal to preserve its public health powers. But doing so is potentially risky; if the ruling striking down the mandate is upheld, that could permanently weaken the agency’s authority.

Source: New York Times

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

GLP-1 Drugs Have Moved Past Weight Loss. Medicine Has Not Fully Caught Up.

Glucagon-Like Peptide–Based Therapies and Longevity: Clinical Implications from Emerging Evidence

Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...

Read more

Join Our Newsletter!